CompoAtlas

Strong Bones VI

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
Vitamine K2

Quelle : Ménaquinone 4

0,00692 mg27,68 µg
Phosphate de calcium, hydroxyde

Quelle : Durapatite

Stärke : 18,5 % Phosphorus

Nicht angegebenNicht berechnet
Phosphate de calcium, hydroxyde

Quelle : Durapatite

Stärke : 39,9 % Calcium

300 mgNicht berechnet
Extrait de pépins de raisin

Quelle : Vitis vinifera - Graine

Extrakt : Matériel brut sec

Extraktionsverhältnis : 75:1

Trockenpflanzenäquivalent : 375 mg

Stärke : 80 % Oligomeric proanthocyanidins

5 mgNicht berechnet
Manganèse

Quelle : Citrate de manganèse (II)

0,2325 mg930 µg
Vitamine C

Quelle : Acide ascorbique

15,5 mg62.000 µg
Lycopène

Quelle : Solanum lycopersicum - Chair (fruit)

0,4166 mgNicht berechnet
Mentha x piperita

Quelle : Mentha X piperita - feuille

7,501 mgNicht berechnet
Camellia sinensis

Quelle : Camellia sinensis - feuille

Extrakt : Matériel brut sec

Extraktionsverhältnis : 20:1

Trockenpflanzenäquivalent : 70 mg

Stärke : 75 % Epigallocatechin 3-gallate

3,5 mgNicht berechnet
Magnésium

Quelle : Bisglycinate de magnésium

13,01 mg52.040 µg

Nicht arzneiliche Inhaltsstoffe

Eau purifiée, Dioxyde de silicium, Hypromellose, Stéarate de magnésium

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
Adultesminimum : 19 ans4 Capsule1 Tous les jours

In Kanada zugelassene Verwendungen

Calcium intake, when combined with sufficient Vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. For maintaining general health. Helps in collagen formation to maintain healthy bones, cartilage, teeth and/or gums. Helps in the absorption (and use) of calcium and phosphorus. Helps in the development and maintenance of bones, cartilage, teeth and/or gums and in connective tissue formation. Helps maintain healthy skin and connective tissue formation. Helps normal growth. Helps to build strong bones and teeth. Helps to maintain healthy bones, hair, nail and/or skin. Helps to produce and repair connective tissue. Source of/An antioxidant for the maintenance of good health. Vitamin and mineral supplement. Helps in the development and maintenance of bones and teeth (especially in children and young adults).Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may reduce the risk of developing osteoporosis (in peri- and postmenopausal women) (in later life).Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may help prevent bone loss/osteoporosis (in peri- and postmenopausal women) (in later life).As part of a healthy diet (when taken with Vitamin D) may help prevent bone loss/osteoporosis.Helps support bone health.Helps in energy metabolism, tissue formation and bone development.Helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise in post-menopausal women. Helps to minimize discomfort due to moderate intensity aerobic exercise in postmenopausal women. Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise in post-menopausal women. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise in post-menopausal women. Helps to improve recovery from joint pain and stiffness due to moderate intensity aerobic exercise.Helps to minimize discomfort due to moderate intensity aerobic exercise.Helps reduce levels of CTX-II, a biomarker/marker of cartilage degradation due to moderate intensity aerobic exercise. Helps reduce levels of CTX-II, a biomarker/marker of joint degradation due to moderate intensity aerobic exercise. (NEM) Starts to reduce joint pain due to moderate intensity aerobic exercise in as little/as quickly as 1 day and joint stiffness in as little/as quickly as 5 days. (NEM is) Clinically proven to provide relief from joint stiffness due to moderate intensity aerobic exercise (in as little as 5-7 days).(NEM) Helps provide relief from joint pain due to moderate intensity aerobic exercise (as quickly as the first day).Helps maintain healthy calcium metabolism.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Cautions and Warnings : Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking blood thinners. Consult a health care practitioner if symptoms persist or worsen. Stop use and consult a health care practitioner if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite. Consult a health care practitioner prior to use if you have a liver disorder or an iron deficiency. Consult a health care practitioner prior to use if you have gallstones or anemia. Consult a health care practitioner prior to use if you have asthma or peptic ulcer disease. Consult a health care practitioner prior to use if you are taking anticoagulants or products containing acetylsalicylic acid (ASA) or other salicylates. Consult a health care practitioner prior to use if you have been diagnosed with estrogen-dependent cancer or have a kidney disorder. Consult a health care practitioner prior to use if you have a bile duct obstruction, stomach ulcers or excess stomach acid.

Originaltext auf Englisch.

Contra-Indications : Do not use if you have a known allergy to eggs or egg-by-products. Do not use this product if you are allergic to acetylsalicylic acid (ASA) or other salicylates. Do not use this product if you are pregnant or breastfeeding.

Originaltext auf Englisch.

Produktdaten

Inhaber
Vitazan Herbs and Vitamins Inc
NPN oder DIN-HM
80115703
Status
Aktive Lizenz
Lizenzdatum
20. Januar 2022
Überarbeitungsdatum
Nicht angegeben
Form
Capsule
Verabreichungsweg
Orale
Art des Antrags
Générale (non traditionelle)

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80115703

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • Mentha x piperita
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    PEPPERMINT - MENTHA X PIPERITA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).

    Von Health Canada zitierte Quellen (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Anwendungsbedingung: Essential oil.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Von Health Canada zitierte Quellen (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: Essential oil.

    When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).

    Von Health Canada zitierte Quellen (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).

    Von Health Canada zitierte Quellen (2)
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Monografie von Health Canada vom 27. Februar 2026

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Das Belegdatum dieser Zutatenliste ist unbekannt.

Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile